GlobeNewswire

Oxford Immunotec Reports First Quarter 2019 Financial Results

Del
  • First quarter revenue of $14.8 million, an increase of 27% compared to prior year period
  • Gross margins expanded 360bps to 71.4%
  • 86% reduction in net loss to $1.5m

OXFORD, United Kingdom and MARLBOROUGH, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announced first quarter 2019 financial results.


“The Company got off to a strong start in 2019 with robust growth in all geographies and continued execution on our strategic priorities” said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. “As we repurpose the Company around our more focused business model, we are starting to see the emergence of higher growth, and improving profitability metrics.”

By revenue type, total revenues were, in millions:

    Three Months Ended March 31,
    2019   2018   Percent
Change
             
Product $ 13.8 $ 10.1       37 %
Service   1.0   1.6   (39 )%
Total Revenue $ 14.8 $ 11.7   27 %
             

By geography, total revenues were, in millions:

    Three Months Ended March 31,  
            Percent Change  
    2019   2018   As
Reported
(1)
  Constant
Currency
(2)
 
                   
United States $ 5.5 $ 3.7       50 %       50 %  
Europe & ROW   2.8   2.2   24 %   32 %  
Asia   6.5   5.8   13 %   15 %  
Total Revenue $ 14.8 $ 11.7   27 %   29 %  
                   

(1) Oxford Immunotec completed its sale of the Company’s U.S. laboratory services business on November 6, 2018. As such, Total Revenue, Product Revenue, and United States Revenue for the three months ended March 31, 2019 and March 31, 2018 are not fully comparable. Total Revenue, Product Revenue, and United States Revenue for the three months ended March 31, 2018 include sales to our former U.S. laboratory services business at our intercompany transfer price that were formerly eliminated in consolidation. Total Revenue, Product Revenue, and United States Revenue for the three months ended March 31, 2019 include revenue from T-SPOT®.TB test kits and related accessories sold to Quest Diagnostics under the terms of a long-term supply agreement.

(2) Changes in revenue include the impact of changes in foreign currency exchange rates. We use the non-GAAP financial measure "constant currency basis" in our filings to show changes in our revenue without giving effect to period-to-period currency fluctuations. We consider the use of a period over period revenue comparison on a constant currency basis to be helpful to investors, as it provides a revenue growth measure free of positive or negative volatility due to currency fluctuations.

First Quarter 2019 Financial Results

Revenue for the first quarter of 2019 was $14.8 million, representing a 27% increase from first quarter 2018 revenue of $11.7 million. On a constant currency basis, revenue increased 29% versus the prior year period.

2019 first quarter product revenue was $13.8 million, representing a 37% increase from product revenue of $10.1 million in the first quarter of 2018. The increase was primarily attributable to higher revenue in all geographical regions. Service revenue for the first quarter of 2019 was $0.9 million, a 39% decrease from 2018 first quarter service revenue of $1.6 million. The decrease in service revenue resulted from the company’s exit from the blood donor screening business, partially offset by growth in tuberculosis testing volumes at our U.K. Oxford Diagnostic Laboratories.

United States revenue was $5.5 million in the first quarter of 2019, representing a 50% increase from revenue of $3.7 million in the prior year period. The increase was due to increased tuberculosis testing volumes and a higher selling price compared to the intercompany transfer price utilitised for the prior year period; offset by a decline in revenue from the Company’s exit from the blood donor screening business.

Europe & rest of world, or Europe & ROW, revenue was $2.8 million in the first quarter of 2019, representing a 24% increase compared to the first quarter of 2018. On a constant currency basis, Europe & ROW increased 32% versus the first quarter of 2018. The increase was driven by strong tuberculosis revenue growth in the U.K., continental European markets and countries outside of Europe.

Asia revenue was $6.5 million in the first quarter of 2019, representing an increase of 13% compared to 2018 first quarter revenue of $5.7 million. On a constant currency basis, Asia revenue increased 15% versus the first quarter of 2018. The increase was due primarily to growth in revenues in China and other Asian countries.

Gross profit for the first quarter of 2019 was $10.6 million, an increase of approximately $2.6 million from gross profit of $7.9 million in the same period of 2018. Gross margin was 71.4%, an increase of 360 basis points from gross margin of 67.8% in the first quarter of 2018. The first quarter 2019 gross margin improvement was driven by the Company’s exit from the blood donor screening business, the change in pricing from the intercompany transfer price in the prior year period, as well as from operational improvements.

Operating expenses were $13.9 million in the first quarter of 2019, a decrease of approximately $1.4 million compared to $15.3 million in the first quarter of 2018.

Net loss for the first quarter of 2019 was $1.5 million, or $0.06 per share, compared to $10.3 million, or $0.40 per share, in the first quarter of 2018. Net loss per share was based on 26,515,871 and 25,718,910 weighted average ordinary shares outstanding for the first quarters of 2019 and 2018, respectively. 

EBITDA for the first quarter of 2019 was $(3.8) million compared to $(7.2) million in the first quarter of 2018. Adjusted EBITDA was $(2.3) million for the first quarter of 2019 compared to $(5.4) million in the same period in 2018. Both EBITDA and Adjusted EBITDA are non-GAAP measures.

Business Outlook

For full year 2019, the Company continues to expect revenue of between $69 and $72 million. Based off the mid-point of this annual revenue guidance range, the company expects 27 to 28% of full year revenues to fall in the second quarter.

Conference Call

Oxford Immunotec will host a conference call on Thursday, May 9, 2019 at 8:00 a.m. Eastern Daylight Time to discuss its first quarter 2019 financial results. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers and +1 (484) 365-2897 for international callers and reference confirmation code 6687808 approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on the Company's website for approximately 60 days.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary assays for immunology and infectious disease. The Company's T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com.

T-SPOT, the Oxford Immunotec logo, ODL, and the Oxford Diagnostic Laboratories logo are trademarks of Oxford Immunotec Limited. Immunetics is a trademark of Immunetics, Inc.

Forward-Looking Statements

This release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this release are forward-looking statements. This includes statements about Oxford Immunotec's anticipated plans and objectives, future performance and revenues, financial condition, prospects for sales of its products, growth, strategies, expectations and objectives of management. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements contained in this release reflect Oxford Immunotec's current expectations and are subject to risks and uncertainties. Actual results may differ materially from those projected or implied by forward-looking statements. Other factors that could adversely affect Oxford Immunotec's business and prospects are described under the "Risk Factors" section in its filings with the Securities and Exchange Commission ("SEC"). Oxford Immunotec's SEC filings are available for free by visiting the investor section of its website, www.oxfordimmunotec.com, or the SEC's website, www.sec.gov.

Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. Investors should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. Oxford Immunotec does not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.

CONTACTS:

For Media and Investor Inquiries:
Matt McLaughlin
Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953
mtmclaughlin@oxfordimmunotec.com


Oxford Immunotec Global PLC
Condensed consolidated statements of operations
(unaudited)

        Three months ended March 31,
(in thousands, except share and per share data)             2019       2018  
Revenue:                
Product           $ 13,841     $ 10,129  
Service             948       1,550  
Total revenue             14,789       11,679  
Cost of revenue:                
Product             3,915       2,652  
Service             313       1,107  
Total cost of revenue             4,228       3,759  
Gross profit             10,561       7,920  
Operating expenses:                
Research and development             2,324       2,366  
Sales and marketing             6,279       7,151  
General and administrative             5,208       5,560  
Settlement expense             99       207  
Total operating expenses             13,910       15,284  
Operating loss from continuing operations             (3,349 )     (7,364 )
Other expense:                
Interest income (expense), net             1,200       (604 )
Foreign exchange losses             (884 )     (103 )
Other expense                     (52 )
Loss from continuing operations before income taxes             (3,033 )     (8,123 )
Income tax benefit (expense) from continuing operations             1,537       (63 )
Loss from continuing operations             (1,496 )     (8,186 )
Discontinued operations:                
Loss from discontinued operations before income taxes                     (2,140 )
Income tax expense                        
Loss from discontinued operations                     (2,140 )
Net loss           $ (1,496 )   $ (10,326 )
                 
Net loss per ordinary share—basic and diluted:                
Loss from continuing operations           $ (0.06 )   $ (0.32 )
Loss from discontinued operations                     (0.08 )
Net loss           $ (0.06 )   $ (0.40 )
                 
Weighted-average shares used to compute net loss per ordinary share—basic and diluted             26,515,871       25,718,910  
                 


Reconciliation of net loss to Adjusted EBITDA (1)
(unaudited)

        Three months ended March 31,
(in thousands)             2019       2018  
Net loss           $ (1,496 )   $ (10,326 )
Loss from discontinued operations                     (2,140 )
Loss from continuing operations             (1,496 )     (8,186 )
Income tax (benefit) expense             (1,537 )     63  
Interest (income) expense, net             (1,200 )     464  
Depreciation and amortization expense             470       341  
Accretion and amortization of loan fees                     140  
EBITDA             (3,763 )     (7,178 )
                 
Reconciling items:                
Share-based compensation expense             845       1,760  
Unrealized exchange losses (gains)             549       (159 )
Settlement expense             99       207  
Adjusted EBITDA           $ (2,270 )   $ (5,370 )
                 

(1) EBITDA and Adjusted EBITDA are non-GAAP measures that we calculate as net loss, adjusted for the impact of earnings or charges resulting from matters that we consider not to be indicative of our ongoing operations. We believe that these measures provide useful information to investors in understanding and evaluating our operating results in the same manner as our management and Board of Directors. Our presentation of these measures is not made in accordance with U.S. GAAP, and our computation of these measures may vary from others in the industry. Our use of these measures has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under U.S. GAAP.

The above table presents a reconciliation of net loss, the most comparable U.S. GAAP measure, to EBITDA and Adjusted EBITDA for each of the periods indicated.

Oxford Immunotec Global PLC
Condensed consolidated balance sheets
(unaudited)

    March 31,   December 31,
(in thousands, except share and per share data)     2019       2018  
Assets        
Current assets:        
Cash and cash equivalents   $ 189,518     $ 192,844  
Accounts receivable, net     10,153       9,158  
Other receivable     4,562       4,500  
Inventory, net     9,944       7,767  
Prepaid expenses and other assets     4,038       2,511  
       
Total current assets     218,215       216,780  
Restricted cash, non-current     100       100  
Other receivable     4,500       4,500  
Property and equipment, net     7,066       7,144  
Operating lease right-of-use assets     7,223          
Goodwill     2,483       2,483  
Other intangible assets, net     56       61  
Deferred tax asset     1,667       1,052  
         
Total assets   $ 241,310     $ 232,120  
         
Liabilities and shareholders’ equity        
Current liabilities:        
Accounts payable   $ 3,115     $ 2,801  
Accrued liabilities     9,377       10,891  
Current portion of operating lease liability     484          
Settlement liability     4,130       4,106  
Deferred income     213       125  
Current portion of loans payable             85  
         
Total current liabilities     17,319       18,008  
Long-term portion of operating lease liability     7,782          
Long-term portion of loans payable     30       106  
         
Total liabilities     25,131       18,114  
         
Shareholders’ equity:        
Ordinary shares, £0.006705 nominal value; 38,978,604 shares authorized at March 31, 2019
   and December 31, 2018, and 26,623,057 and 26,439,334 shares issued and outstanding at
   March 31, 2019 and December 31, 2018, respectively
    278       276  
Additional paid-in capital     305,515       303,015  
Accumulated deficit     (82,258 )     (80,762 )
Accumulated other comprehensive loss     (7,356 )     (8,523 )
         
Total shareholders’ equity     216,179       214,006  
         
Total liabilities and shareholders’ equity   $ 241,310     $ 232,120  
         

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Gainsight Unveils the Customer Cloud, the Future of Customer Success Technology23.5.2019 19:30:00 CESTPressemelding

New Products Announced at Pulse 2019 to Drive Customer Success Across the Enterprise SAN FRANCISCO, May 23, 2019 (GLOBE NEWSWIRE) -- Today, Gainsight® launched the Customer Cloud —a first-of-its-kind solution for subscription businesses looking to adopt a customer-centric philosophy that enables them to retain customers while also driving company growth post-sale. According to the 2018 Subscription Economy Index report, subscription companies are growing five times faster than S&P and retail sales. The Gainsight Customer Cloud caters to these businesses by combining the company’s Customer Success and Product Experience products with three new product innovations to offer a powerful set of solutions for businesses to optimize their subscription strategies through technology. “With the maturity of cloud technology and the subscription economy, customer expectations have drastically changed. Companies are struggling to leverage existing tools to satisfy the increasing demands of their cus

Lowered Return Expectations Among Several Trends Pointing to a Shift in Private Markets Due Diligence says New eVestment Survey23.5.2019 15:30:00 CESTPressemelding

ATLANTA, May 23, 2019 (GLOBE NEWSWIRE) -- Private markets funds have continued to rake in new commitments from institutional investors eager to diversify their portfolios and capture the returns private markets investments can offer. However, investors are now tempering their private markets return expectations. Coupled with other industry trends, this will have implications for private markets fundraising and due diligence according to a new eVestment report, produced in association with parent company Nasdaq. The 2019 eVestment Private Markets Due Diligence Survey of institutional investors, consultants and private markets fund managers finds that 52% of investors expect returns in the space to decline in the future (page 16). Only 12% of investors expected private equity returns to increase, with the balance – 36% – expecting returns to stay about the same. Forty-seven percent of investors surveyed expect to see lower returns in venture capital vs. just 16% of investors who expect r

Collibra Announces 2019 Excellence Awards Winners23.5.2019 15:00:00 CESTPressemelding

American Express, Deloitte, and Lloyds Banking Group recognized as leaders in harnessing data to drive digital transformation NEW YORK, May 23, 2019 (GLOBE NEWSWIRE) -- Collibra, the leader in enterprise data governance and catalog software, today announced the winners of the 2019 Collibra Excellence Awards. Presented at the annual Data Citizens conference in New York, the awards honor teams and individuals driving innovative data strategy by collaborating with Collibra. “In today’s market, organizations that are able to maximize data have the power to transform entire industries,” said Felix Van de Maele, co-founder and CEO of Collibra. “We’re proud to honor the recipients of the Collibra Excellence Awards, a cutting-edge group at the forefront of data-driven innovation.” The 2019 Collibra Excellence Award Winners: American Express — Distinguished Data Program of the Year American Express was recognized for its data governance transformation, which began as a compliance initiative and

XBiotech Announces Plan to Launch Randomized Phase 2b Study of Bermekimab in Hidradenitis Suppurativa23.5.2019 14:20:00 CESTPressemelding

AUSTIN, Texas, May 23, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced plans to advance its dermatology program for its true human antibody bermekimab with the launch of a randomized, double-blind, placebo controlled, Phase 2b clinical study in patients with moderate to severe Hidradenitis Suppurativa (HS). This Phase 2b study will evaluate safety and efficacy of bermekimab at different subcutaneous doses compared with placebo. The study will further evaluate efficacy of bermekimab in HS and guide dosing strategies for the anticipated Phase 3 registration study. The Company expects the first patient to be enrolled during the third quarter of 2019. The Phase 2b study follows two previous successful clinical studies of bermekimab to treat HS. XBiotech recently evaluated bermekimab in a phase 2 study involving two groups of patients with HS: those who had no prior treatment with biologics; and those who had failed the only approved biological therapy to treat HS. The study, whi

LGC CAPITAL Announces Results of Annual Meeting, Appointment of New Chairman and Approval of Name Change to Elixxer Ltd.23.5.2019 14:00:00 CESTPressemelding

MONTRÉAL, May 23, 2019 (GLOBE NEWSWIRE) -- LGC Capital Ltd. (TSXV: LG) (OTCQB: LGGCF) ("LGC" or the “Corporation”) is pleased to announce the results of its annual and special meeting of shareholders (the “Meeting”) held yesterday in Montreal, Quebec. At the Meeting, all five of the nominees listed in the Corporation’s management information circular dated April 17, 2019 were elected as directors, all with a vote of more than 92% of the shares voted in their favour. Accordingly, the directors of LGC for the ensuing year are Mohammed Ghafari, Mazen Haddad, Rafi Hazan, David Lenigas and Ferras Zalt. At the Meeting, shareholders adopted a special resolution approving a change in the name of the Corporation to “Elixxer Ltd.” or such other name as the Corporation’s directors may determine. The special resolution was supported by 98.94% of the votes cast at the Meeting. The Corporation intends to proceed with the name change as expeditiously as possible. Shareholders also adopted: a special

Merus Announces 2019 Annual General Meeting of Shareholders23.5.2019 14:00:00 CESTPressemelding

UTRECHT, The Netherlands, May 23, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that the 2019 Annual General Meeting of Shareholders will be held on June 12, 2019 at 1:00 pm (CEST) at the offices of NautaDutilh N.V. (address: Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands). All relevant documents and information for the meeting, including the notice and agenda, are available in the 'Investor Relations' section of Merus’ website (www.merus.nl) under “Financial Information”. About Merus N.V. Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clin